EmailStory Stocks®
Archive
Last Update: 28-Dec-11 09:53 ET
S&P Health Care Sector -0.7%, Underperforming the S&P 500
The Healthcare sector is lower by 0.6%, slightly outperforming the broader market -0.4%.
News: ANAC (+0.7%) filed for $50 mln mixed securities shelf offering. IMMU (-0.2%) and UCB announced restructuring of Epratuzumab license agreement; IMMU will receive $30 mln; UCB permitted to sublicense in certain territories. VRUS (-0.2%) and Gilead Sciences (GILD -0.1%) filed merger supplement documents. EBS (-1.5%) announced plans for TRU-016 program following termination of collaboration with Abbott (ABT -0.3%). SNY (-0.2%) issued update on share repurchases. ALNY (-1.3%) announced publication of pre-clinical results with ALN-HTT, an RNAi Therapeutic for the treatment of Huntington's Disease, in experimental neurology - was well tolerated in these studies. CHDX (-0.6%) announced the appointment of Lawrence Pemble as COO; effective January 1, 2012.
Earnings/Guidance: MRX (-2.3%) lowered Q4 earnings/revs guidance below consensus; provided updates on its corporate initiatives.
Broker Research: Nothing of Interest.
Other: MJN (+0.7%): Articles out overnight discuss third infant with Cronobacter infection in Oklahoma -- report indicates this infant had not consumed Enfamil formula.
News: ANAC (+0.7%) filed for $50 mln mixed securities shelf offering. IMMU (-0.2%) and UCB announced restructuring of Epratuzumab license agreement; IMMU will receive $30 mln; UCB permitted to sublicense in certain territories. VRUS (-0.2%) and Gilead Sciences (GILD -0.1%) filed merger supplement documents. EBS (-1.5%) announced plans for TRU-016 program following termination of collaboration with Abbott (ABT -0.3%). SNY (-0.2%) issued update on share repurchases. ALNY (-1.3%) announced publication of pre-clinical results with ALN-HTT, an RNAi Therapeutic for the treatment of Huntington's Disease, in experimental neurology - was well tolerated in these studies. CHDX (-0.6%) announced the appointment of Lawrence Pemble as COO; effective January 1, 2012.
Earnings/Guidance: MRX (-2.3%) lowered Q4 earnings/revs guidance below consensus; provided updates on its corporate initiatives.
Broker Research: Nothing of Interest.
Other: MJN (+0.7%): Articles out overnight discuss third infant with Cronobacter infection in Oklahoma -- report indicates this infant had not consumed Enfamil formula.
